Related Experiment Video
Updated: Jun 25, 2025
Real-time Imaging of Leukotriene B4 Mediated Cell Migration and BLT1 Interactions with β-arrestin
Published on: December 23, 2010
Targeting leukotriene biosynthesis to prevent atherosclerotic cardiovascular disease
Xiaomeng Wang1, Lohendran Baskaran2, Mark Chan3
1Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore Medical School, Singapore.
Insights
Targeting leukotriene synthesis may prevent atherosclerosis progression. Inhibiting 5-lipoxygenase (5-LO) and 5-lipoxygenase-activating protein (FLAP) shows therapeutic potential for cardiovascular disease by reducing inflammation.
Area of Science:
- Cardiovascular Science
- Inflammation Biology
- Pharmacology
Background:
- Atherosclerotic cardiovascular disease (ASCVD) is a major global health burden, necessitating novel preventive and therapeutic strategies.
- Inflammation critically drives atherosclerosis development and progression, making it a key therapeutic target for vascular protection.
- Leukotrienes, pro-inflammatory mediators, are implicated in atheroma inflammation and progression, with genetic links to cardiovascular disease risk.
Purpose of the Study:
- To review studies on leukotriene synthesis inhibition for cardiovascular disease.
- To highlight the therapeutic potential of targeting leukotriene pathways in ASCVD.
Main Methods:
- Overview of pre-clinical and early clinical studies investigating leukotriene synthesis inhibitors.
- Examination of genetic associations between leukotriene pathway components and cardiovascular disease risk.
Main Results:
- Genetic mutations in 5-lipoxygenase (5-LO) and 5-lipoxygenase-activating protein (FLAP) correlate with increased cardiovascular disease risk.
- Pharmacological inhibition of 5-LO and FLAP has demonstrated efficacy in preventing atheroma formation in experimental models and early human studies.
Conclusions:
- Targeting leukotriene synthesis represents a promising therapeutic strategy for preventing atheroma inflammation and progression.
- Inhibition of 5-LO and FLAP may improve outcomes for patients at risk of ASCVD.
Abstract:
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death and disability worldwide. As such, new treatments are needed to prevent the onset and progression of atherosclerosis to improve outcomes in patients with coronary, cerebrovascular, and peripheral arterial disease. In this regard, inflammation is known to be a critical driver of atherosclerosis formation and progression, thus it is a viable target for vascular protection in patients at risk of developing ASCVD. Leukotrienes, key pro-inflammatory lipid mediators derived from arachidonic acid, are associated with atheroma inflammation and progression. Genetic mutations in key components of the leukotriene synthesis pathway, such as 5-lipoxygenase (5-LO) and 5-lipoxygenase-activating protein (FLAP), are associated with an increased risk of cardiovascular disease, and pharmacological inhibition of 5-LO and FLAP has been reported to prevent atheroma formation in pre-clinical and early clinical studies. In this article, we provide an overview of these studies and highlight the therapeutic potential of targeting leukotriene synthesis to prevent atheroma inflammation and progression and improve outcomes in patients at risk of ASCVD.
Related Concept Videos
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
01:17Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:28Antihypertensive Drugs: Types of β-Blockers